Ganitumab ELISA Kit (KDC29904)

Colorimetric

Plasma, Serum

Quantitative

0.31-5 μg/mL

0.156 μg/ml

CV<20%

80-120%

2-8 ℃

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Ganitumab (AMG-479) is a mAb against IGF-IR which also inhibits binding of both IGF-1 and IGF-2 ligands to IGF-IR. The therapeutic value of AMG-479 was evaluated in several preclinical settings including androgen-dependent prostate cancer, and combined with androgen-deprivation therapy. Ganitumab was found to be most potent against VCaP xenografts when it was used in combination with complete androgen-deprivation therapy. After 4 weeks of treatment, tumor volume was reduced by 72% and growth suppression was maintained over 16 weeks of treatment. These findings suggested that the use of ganitumab in conjunction with androgen-deprivation therapy may be beneficial in the treatment of prostate cancer.